NASDAQ:APLS 30 October 2025

Apellis (APLS) stock slides 15% after $689 mln 2025 revenue preview at JPM conference

Apellis shares fell 14.7% to $23.29 after the company projected 2025 U.S. net product revenue of about $689 million and reported rising demand for SYFOVRE. EMPAVELI’s 2025 U.S. revenue is expected to reach $102 million. Management updates are expected at the J.P. Morgan Healthcare Conference.

12 January 2026

Earnings Reports·NASDAQ:APLS·Stock Market

Apellis stock jumps nearly 8% as investors look to JPM healthcare update

Apellis Pharmaceuticals shares climbed nearly 8% to $25.85 midday Wednesday as investors positioned ahead of the company’s Jan. 12 presentation at the J.P. Morgan Healthcare Conference. Traders are watching for updates on Syfovre and Empaveli, with recent SEC filings and competitive pressures drawing attention to the stock’s moves.

7 January 2026

NASDAQ:APLS·Stock Market

Apellis’ $458M Shocker: FDA Win, Analyst Buzz & 20% Stock Whiplash

Apellis Pharmaceuticals reported Q3 2025 revenue of $458.6 million and a $215.7 million net profit, but its stock fell about 21% after management warned of future losses. Syfovre sales in the U.S. were flat at $150.9 million, with modest injection growth and ongoing debate over its benefits. Empaveli gained FDA approval for rare kidney diseases in July. Analyst ratings and price targets remain divided.

30 October 2025

NASDAQ:APLS·Stock Market

Southwest Gas Gains from Growing Customer Base and Strategic Investments
March 20, 2026, 2:29 PM EDT. Southwest Gas (SWX) leverages contributions from an expanding customer base, driven by regional economic growth and new rate structures. The company installed 37,000 new meter sets in 2025, supporting a 1.6% rise in customers. Planned capital investments of $1.25 billion in 2026 and $6.3 billion through 2030 aim to enhance infrastructure and reliability. SWX maintains lower debt than peers, boosting financial flexibility. However, reliance on interstate pipelines poses supply risks. Shares rose 5% over three months, trailing the industry's 7.4% gain. SWX holds a Zacks Rank #4 (Sell), while peers Atmos Energy, Chesapeake Utilities, and Northwest Natural have stronger buy ratings and higher projected earnings growth.